Forecast

The analysts' average price target is €4.36 (+754.90%). The median is €4.36 (+754.90%).

Buy	2
Hold	1
Sell	0

News Go to news feed

Fractyl Health expects pivotal REMAIN-1 data on Revita in early Q4 2024

Fractyl Health presented Revita at the Morgan Stanley conference as an endoscopic procedure intended to stabilize weight loss achieved with GLP-1 after treatment cessation. The approval‑relevant REMAIN‑1 study enrolled more than 300 patients; all 6‑month visits are complete and data analysis is under way. Revita has FDA Breakthrough Device status and is pursuing a de‑novo regulatory path with a target for US approval by the end of 2027 and a market launch in early 2028; commercial rollout is planned to be focused on 100–200 bariatric competence centers. Fractyl had under $50 million in cash at the end of Q2 2024 and is exploring non‑dilutive financing options to reach approval and initial commercialization. » More on de.investing.com
Fractyl Health introduces Revita: focus on weight maintenance after GLP‑1 therapy

Fractyl Health presented data at the H.C. Wainwright conference showing that the endoscopic Revita procedure substantially reduces weight regain after stopping GLP‑1 medications and has a favorable safety profile. The company expects pivotal top-line data in early Q4 2026 and plans a De Novo submission in late Q4 2026, with FDA feedback indicating a possible class II designation. Fractyl reports $47 million in cash, sees significant commercial potential, but remains dependent on approval, reimbursement and market acceptance. » More on de.investing.com
H.C. Wainwright puts Fractyl Health in focus and sees Revita approval in 2027

H.C. Wainwright identifies Fractyl Health as a promising biotech opportunity and sees potential approval of the Revita treatment in 2027 with market launch in early 2028. The investment firm praises the commercial strategy of centers of excellence and existing infrastructure, which could enable a capital-efficient model and cash profitability within five to eight quarters after market entry. Analysts expect interim data from a 45‑patient cohort to support the design of a pivotal study of about 315 patients, as well as a possible de novo submission in Q4 2026. Fractyl recently reported Q2 results that beat analyst expectations and showed a smaller loss per share due to reduced R&D spending. » More on de.investing.com

Financials

In the last quarter, FRACTYL HEALTH INC. O.N. Aktie had revenue of €0 and net profit of -€22.38m

(EUR)	June 2026	YoY
Revenue	0	-
Gross profit	0	-
Net profit	-22.38m	5.43%
EBITDA	-21.89m	6.60%

Fundamentals

Metric	Value
Market capitalization	€77.86m
Number of shares	158.65m
52-week high/low	€2.13 - €0.33
Dividends	No
Beta	2.33
P/E ratio	-0.51
PEG ratio	-0.01
P/B ratio	-53.60
P/S ratio	0.00

Company profile

Fractyl Health, Inc. ist ein Unternehmen für Stoffwechseltherapeutika und entwickelt Therapien zur Behandlung von Typ-2-Diabetes (T2D) und Adipositas. Das Unternehmen entwickelt das Revita DMR System (Revita), ein ambulantes Therapieverfahren zur dauerhaften Veränderung der Duodenaldysfunktion, einer pathologischen Folge einer fett- und zuckerreichen Ernährung, die beim Menschen T2D und Fettleibigkeit auslösen kann. Darüber hinaus entwickelt das Unternehmen Rejuva, eine neuartige Gentherapieplattform für die Bauchspeicheldrüse, die eine langfristige Remission von T2D und Fettleibigkeit ermöglichen soll, indem sie die Funktion von Stoffwechselhormonen in den Inselzellen der Bauchspeicheldrüse von Patienten dauerhaft verändert. Fractyl Health, Inc. war früher als Fractyl Laboratories Inc. bekannt und änderte am 09. Juni 2021 seinen Namen in Fractyl Health, Inc. Das Unternehmen wurde im Jahr 2010 gegründet und hat seinen Sitz in Lexington, Massachusetts.